Last updated on February 2018

Study of Safety Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma Chronic Lymphocytic Leukemia and Waldenstrom's Macroglobulinemia


Brief description of study

This is a phase I study of BTK inhibitor CT-1530 in patients with relapsed or refractory B cell non-Hodgkin lymphoma (B-NHL), chronic lymphocytic leukemia (CLL) or Waldenstrom's macroglobulinemia (WM).

The purpose of the study is to determine the MTD/RP2D of CT-1530, and evaluate its safety and tolerability as monotherapy in subjects with relapsed or refractory B cell non-Hodgkin lymphoma (B-NHL), chronic lymphocytic leukemia (CLL) or Waldenstrom's macroglobulinemia (WM).

Clinical Study Identifier: NCT02981745

Contact Investigators or Research Sites near you

Start Over

Yuankai Shi, MD

Cancer Hospital of Chinese Academy of Medical Sciences
Beijing, China
  Connect »